Sativex, a ground-breaking cannabis-based drug for treating symptoms of multiple sclerosis (MS), could be approved in the UK by the end of June, its creator said on Thursday.
By Rachel Cooper - Published: 6:45AM BST 21 May 2010
GW Pharmaceuticals has been developing Sativex, which eases muscle stiffness associated with MS, for more than a decade and on Thursday the drug maker said the medicine could be approved and launched in Britain by the end of next month.
A regulatory green light in Spain is expected shortly after, according to the company, which added that all major and minor issues relating to the application for Sativex's approval had been resolved.
The approval is now in its final stage, which involves finalising the wording on the product's packaging.
Sativex, which is sprayed under the tongue, is to be marketed in Britain by Germany's Bayer and in the rest of Europe by Spain's Almirall.
GW said both partners were well advanced in preparations for the Sativex launch and GW has manufactured stocks of Sativex for distribution immediately upon UK approval.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
"Providing You with 'MS Views and News', is What We Do"
Remain up-to-date and Informed with Multiple Sclerosis News and Information. If not yet receiving the"Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org. - - Thank you -
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
0 comments:
Post a Comment